Seeking Alpha

biochemist

biochemist
Send Message
View as an RSS Feed
View biochemist's Comments BY TICKER:
Latest  |  Highest rated
  • 11.2% Dividend Invesco Mortgage Capital's Interest Rate Neutral Strategy May Appeal To Investors [View article]
    David - thank you for the nice analysis. I am long IVR and I agree that it is a buy below $16. I will probably round up my position and lower my cost basis a bit.
    Mar 29, 2015. 07:27 PM | Likes Like |Link to Comment
  • FDA Surprises Everyone With Super-Fast Opdivo Lung Cancer Approval [View article]
    PFE has already done a deal with Merck Serono (Merck KGa) to co-develop MSB0010718C, Merck Serono's anti-PD-L1 inhibitor. It is an exclusive deal precluding either partner from collaborating with any other entities on anti-PD-1/PD-L1 therapies. I don't think it is realistic to assume an eventual PFE buyout of BMY.

    PFE most likely was largely interested in AZN (beyond the tax inversion issue) to acquire MEDI4736, AZN's anti-PD-L1 therapy. AZN is likely the 4th entrant, behind MRK and BMY, already approved in the US for melanoma and now lung cancer for BMY, and Roche.
    Mar 29, 2015. 07:15 PM | Likes Like |Link to Comment
  • Here's The Problem With Prospect Capital [View article]
    Chris - excellent analysis and article. I am a bit behind in my reading but I will still comment about my own experience.

    Like Wine Maker (and I'm sure many others on this comment thread), I too have learned a great deal about BDCs in general and about individual companies in particular from contributors like BDC Buzz. Please seek out his postings if you desire to learn more about the BDC space.

    I bought a half position in PSEC 4Q12 and doubled up to the full position in 2Q13. My cost basis is $10.70. I enjoyed the high yield, collected the cash, and redeployed it into new holdings (I prefer to accumulate and buy rather than to DRIP). I too monitored PSEC, read the warnings, considered selling before the dividend cut, but elected to hold as per my buy-and-hold approach to investing.

    PSEC makes up 2.7% of my brokerage account stock portfolio (separate from my 401K, roll-over IRA, and Roth IRA). With the close as of Friday I am down $1600, but I have accumulated over $1900 in distributions over that time. So, I am ahead ~$300, not including taxes paid.

    Unless it starts to become apparent that the other shoe will drop, I will continue to hold, collect the reduced dividend, and wait patiently for improved performance and an improved stock price. While I too think that the management fees are exorbitant, PSEC is far from the worst holding that I have ever purchased and it makes up a small, speculative part of my stock portfolio.
    Mar 29, 2015. 06:47 PM | 2 Likes Like |Link to Comment
  • Comparing Annaly Capital Management's BV, Dividend, Risk, And Valuation To Several mREIT Peers - Part 1 [View article]
    Scott - Great analysis. Thank you for the time, effort and thought that you put into it. I own both NLY and ARR and few other mREITs (IVR, MTGE, TWO) and I have been debating adding to a few positions, ARR excluded. Your analysis has solidified my thinking about ARR and NLY.
    Mar 29, 2015. 12:06 PM | 2 Likes Like |Link to Comment
  • Merck: Buyback Plan Not As Impressive As It Appears [View article]
    Good analysis Stone Fox. I view MRK as over-valued at present, which is not the time you want them repurchasing shares. I think a much better use of the $10 billion is to look for and purchase additional targeted acquisitions as they were able to do in 2014 (Cubist, Idenix, OncoEthix). Another way to view the announcement is that MRK senior management doesn't see anything currently available worth acquiring, or that anything worth acquiring is over-priced in their view.
    Mar 29, 2015. 07:05 AM | 4 Likes Like |Link to Comment
  • Merck adds $10B to buyback [View news story]
    Good news for shareholders. Looks like a move to boost the share price to $60 and above. I would have liked to see the cash used for another targeted acquisition (Idenix, Cubist, OncoEthix) to supplement the pipeline.
    Mar 24, 2015. 06:47 PM | Likes Like |Link to Comment
  • Is Merck Ready To Soar Or Flop? The Challenging Question Of Predicting Pipeline Potential [View article]
    Pharma Doc - another good article. I agree with you that MRK's acquisitions last year were targeted and smart and will point out that you neglected to include the acquisition of privately held OncoEthix and their bromodomain inhibitor OTX015. This was another smart addition to begin to flesh out their oncology portfolio. I hope to see additional such acquisitions in 2015.
    Mar 23, 2015. 06:43 PM | Likes Like |Link to Comment
  • Invesco Mortgage Capital declares $0.45 dividend [View news story]
    I am going to ride it out also. I've been in since 2011.
    Mar 18, 2015. 01:45 AM | Likes Like |Link to Comment
  • Intellectual Property Company Boasts Strong Dividend [View article]
    I first purchased PDLI in 2009 and sold my entire stake in 2014, near the high. For me, the investment thesis no longer holds and no price is an attractive entry point for me. However, if you're a trader you can probably make some nice money getting in near a bottom, but I don't know where that is as it's been in a steady downward trend since November 2014.
    Mar 16, 2015. 08:54 AM | Likes Like |Link to Comment
  • Intellectual Property Company Boasts Strong Dividend [View article]
    I don't think that people on this comment thread really understand the unique aspects of the Queen et al patents that PDLI was able to ride very successfully for years. This revenue stream is based on patents used by multiple big pharmas for multiple blockbuster drugs. This situation is unlikely to ever happen again. PDLI was extremely fortunate and smart, but with the expiration of the Queen et al patents it is extremely unlikely that they well be able to replace this revenue stream anytime soon. The cash on hand of $280 million is a little more than 1 year's revenue generated from the Queen et al patents. Do you honestly believe that they will be able derive an approximately ~100% yearly return from cash on hand?
    Mar 14, 2015. 04:48 PM | 2 Likes Like |Link to Comment
  • Shell to launch new scrip dividend program [View news story]
    More RDS.A/RDS.B wisdom from Rick D. Thanks Rick.
    Mar 6, 2015. 07:17 PM | Likes Like |Link to Comment
  • FDA clears new indication for Bristol-Myers Squibb's Opdivo [View news story]
    This is really great news for lung cancer patients. The PD-1 inhibitor class (and other immunotherapies under development) could very well fundamentally change the way that we treat cancer.
    Mar 4, 2015. 09:39 PM | 4 Likes Like |Link to Comment
  • Bought General Electric In Roth IRA At $23.86 [View article]
    South Gent - Spot on. Thank you for sharing your history with GE, including the ups and downs. I too am more impressed with Immelt than Welch. I think adding at current levels is something all investors should consider who are interested in a long-term hold.

    Long GE
    Mar 1, 2015. 08:58 PM | Likes Like |Link to Comment
  • Is It Time For Investors To Forgive Banks? S&P 500 2015: Part 4A [View article]
    Chuck - I agree with peterad. You would do all a great service in analyzing the Canadian banks in a future article.. The Canadian banks are very well regulated and came the through the Great Recession with little damage.
    Feb 28, 2015. 06:04 PM | 2 Likes Like |Link to Comment
  • Is It Time For Investors To Forgive Banks? S&P 500 2015: Part 4A [View article]
    Very good analysis
    Feb 28, 2015. 05:48 PM | Likes Like |Link to Comment
COMMENTS STATS
464 Comments
211 Likes